Background: Ectopic pregnancy (EP) is a major reason of maternal mortality and morbidity, affecting 1% to 2% of pregnancies. Whether medically with methotrexate (MTX) or surgically with salpingectomy, managing EP could seriously affect female sexuality and reproductive health. The impact of medication and surgical treatment for EP on future fertility is currently unknown and has not been well explored. Objective: This study examines the future reproductive effects of medication and surgical management for EP. Patients and methods: In this prospective study, 50 EP subjects were involved and randomly subdivided into two groups: (MTX) (Group A, n: 25) and salpingectomy (Group B, n: 25). Anti-Mullerian hormone (AMH), beta-human chorionic gonadotropin (β-HCG), liver enzyme levels, and platelet count were evaluated before and after the treatment protocol. Hysterosalpingography (HSG) has also been conducted three months after therapy for Group A to examine tubal patency. Results: Three months following therapy, the AMH levels significantly decreased in Group A compared with Group B (p=0.04). Also, in Group A, AMH levels after 3 months showed a statistically significant decline contrasted with those at the time of therapy. Conclusion: AMH levels prior to and after medication with a single dose of systemic MTX and unilateral salpingectomy for EP were positive signs. Present medical and surgical therapy methods have no detectable detrimental impact on ovarian reserve.